Amico, K. R. http://orcid.org/0000-0002-4458-6934
Mayer, K. H.
Landovitz, R. J.
Marzinke, M.
Hendrix, C.
McCauley, M.
Wilkin, T.
Gulick, R.
,
Funding for this research was provided by:
AIDS Clinical Trials Group (UM1-AI-068636)
HPTN (UM1-AI068619, UM1-AI068613, UM1-AI068617))
Article History
Accepted: 6 October 2023
First Online: 10 November 2023
Declarations
:
: Dr. Landovitz reports personal fees and nonfinancial support from Gilead Sciences outside the submitted work. Dr. Amico reports a grant from Gilead Sciences outside the submitted work. Dr. Mayer has received research grants from Gilead Sciences and Merck, Inc. outside of the submitted work. Dr. Wilkin has received grant fund (paid to Weill Cornell) from Gilead, GlaxoSmithKline/ViiV Healthcare, and Merck. ADr. Wilkin has served as an ad hoc consultant to GlaxoSmithKline/ViiV Healthcare and Merck. Authors not named here have disclosed no conflicts of interest.